Chronic Plaque Psoriasis– Pipeline Review, 2019

Chronic plaque psoriasis which is the most common form of psoriasis is a papulosquamous disorder which is defined by an erythematous plaque with silvery scales. The diagnosis of chronic plaque psoriasis is of a clinical nature, but generally, a biopsy is undertaken to confirm the diagnosis. It is also referred to as psoriasis vulgaris and some of the common symptoms include raised patches of skin suffering from inflammation which is covered with silvery-white scales or plaques. These symptoms can be found in various parts of the body such as the elbow, scalp, knees, back and can also affect the nails in certain situations.

Current treatment of chronic plaque psoriasis includes a multifaceted approach with the usage of treatment options such as medications and phototherapy. In terms of medications, the treatment can be conducted with topical corticosteroids, biologics, and non-biologics, vitamin D3 analogs and retinoids. One of the critical treatment options for chronic plaque psoriasis is the reduction of stress, which can be undertaken with certain lifestyle changes.

Pharmaceutical companies along with various research institutes have been focusing on studying and developing new treatment options for Chronic Plaque Psoriasis. For instance; ARQ-151, which is being studied by Arcutis, is currently in phase-2 clinical trials for the long-term safety of ARQ-151 cream in adult subjects with chronic plaque psoriasis.

At present around 70% of the pipeline candidates for chronic plaque psoriasis are in the phase-2 and phase-3 stage combined. More than half of the studies are sponsored by industry.

Report Description

The report on ‘Chronic Plaque Psoriasis– Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Chronic Plaque Psoriasis. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Chronic Plaque Psoriasis.

The report on ‘Chronic Plaque Psoriasis– Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Chronic Plaque Psoriasis


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for Chronic Plaque Psoriasis


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary